The AP2A1 target was not announced; it assembled, paper by paper, out of cell biology's most decorated field. These are the names, the institutions and the years that put one alpha subunit at the centre of the map.
Thomas Roth and Keith Porter, working on mosquito oocytes, see dense bristle-coated pits and vesicles at the membrane during yolk protein uptake — the first clear sighting of what becomes clathrin-mediated endocytosis. The "bristles" will take eleven more years to get a name.
Roth T.F., Porter K.R., J. Cell Biol. 20, 313 (1964) · clathrin
At the MRC Laboratory of Molecular Biology in Cambridge, Barbara Pearse purifies the coat protein from pig-brain coated vesicles and names it clathrin — from the Latin for a lattice. The lattice's three-legged building block, the triskelion, becomes one of structural biology's icons.
Pearse B.M.F., J. Mol. Biol. 97, 93 (1975) · biography
Brett Collins, David Owen and colleagues, again at the MRC LMB Cambridge, solve the molecular architecture of the AP2 adaptor core: four subunits — alpha (AP2A1), beta2, mu2, sigma2 — arranged as the organising hub that binds membrane lipid, cargo and clathrin at once. The endocytic coat now has a blueprint, and the blueprint has a centre.
Collins B.M. et al., Cell 109, 523 (2002) — PubMed · AP2 adaptor complex
Eric Macia and colleagues in Tom Kirchhausen's lab at Harvard Medical School introduce dynasore, a cell-permeable inhibitor of dynamin — the GTPase that pinches the finished vesicle off the membrane. Dynasore becomes the field's standard tool, and quietly defines the pattern that persists today: we can jam the scissors, not the hub.
Macia E. et al., Dev. Cell 10, 839 (2006) — PubMed
Jason Mercer, Mario Schelhaas and Ari Helenius (ETH Zürich) publish the field-defining review of virus entry by endocytosis: VSV, dengue, hepatitis C and — partly — influenza all exploit clathrin-mediated uptake. The import hub is not just physiology; it is an attack surface.
Mercer J. et al., Annu. Rev. Biochem. 79, 803 (2010) — PubMed
Lisa von Kleist and colleagues in Volker Haucke's lab (Freie Universität Berlin / Leibniz-FMP) report Pitstop 1 and 2, small molecules built against the clathrin terminal domain (Cell, 2011). Then the field checks itself: Dutta et al. (2012) show Pitstop 2 also blocks clathrin-independent endocytosis, and Willox, Sahraoui & Royle (2014) document its non-specificity. The episode is a masterclass in honest science — and the strongest existing argument that this pathway still lacks a specific inhibitor.
von Kleist L. et al., Cell 146, 471 (2011) — PubMed · Dutta D. et al., PLoS ONE 7, e45799 (2012) — PubMed · Willox A.K. et al., Biol. Open (2014) — PubMed
Saheki & De Camilli (Yale) review how nerve terminals rebuild synaptic vesicles through clathrin-mediated endocytosis — the pathway's most extreme workload. In 2013 the Nobel Prize in Physiology or Medicine goes to James Rothman, Randy Schekman and Thomas Südhof for the machinery of vesicle traffic. Also in 2013, Goh & Sorkin review receptor tyrosine kinase endocytosis — EGFR's route runs through AP2. The import pathway is now Nobel-certified biology.
Saheki Y., De Camilli P., Cold Spring Harb. Perspect. Biol. 4, a005645 (2012) — PubMed · Goh L.K., Sorkin A., Cold Spring Harb. Perspect. Biol. 5, a017459 (2013) — PubMed · Nobel Prize 2013
P. Chantachotikul and colleagues in Shinji Deguchi's lab at the University of Osaka report that AP2A1 piles up along the stress fibres of senescent cells — and that it behaves like a switch: knock AP2A1 down and senescent cells regain youthful, proliferative behaviour; overexpress it in young cells and they drift toward senescence. An endocytosis hub nobody suspected becomes a longevity target overnight. Crucially, the experiments used gene knockdown — there was, and is, no pharmacological AP2A1 antagonist to test. The same year, separate work links AP2A1 to Rab7-driven autophagosome transport in Alzheimer's disease models: the hub keeps widening.
Chantachotikul P. et al., Cellular Signalling 127, 111616 (2025) — PubMed · Wang Y. et al., Alzheimers Res. Ther. 17, 132 (2025) — PubMed
The timeline above leaves an obvious gap: the hub has a structure, a mechanism, a senescence phenotype and a viral role — and no antagonist. Panacea Bio Chem's programme, led by Bogdan Dicoias, designs peptide-based AP2A1 antagonists: in-silico screening of designer amino acid chain candidates against the AP2 alpha hub's membrane-docking and clathrin-recruiting surfaces, then synthesis of the leading designs. A design direction, presented with no fabricated results — because after the Pitstop lesson, this field has earned the right to demand them.
Panacea research programme · no clinical claims